Centauri Therapeutics
Develops Alphamer immunotherapies for infectious diseases, including Gram-negative bacterial infections in high-risk patients
Highlights
- New on EvolcAdded 2026-10-31
About Centauri Therapeutics
Centauri Therapeutics develops immunotherapies using its Alphamer platform, which harnesses naturally occurring anti-glycan antibodies to direct immune responses toward disease targets. Its pipeline includes CTX-187, a clinical candidate for Gram-negative bacterial infections.
The company focuses on infectious disease and treatments for vulnerable and at-risk patients. It is based at Alderley Park near Manchester, UK, and was founded in 2014.
Product: Alphamer immunotherapy platform and drug candidates for infectious diseases, including CTX-187.
Jobs at Centauri Therapeutics
Leadership
- Jennifer Schneider · Chief Executive Officer, DirectorSource: company website
- Samantha Macro · Chief Financial OfficerSource: company website
More biotech & pharma companies
Cerevance
Develops cell-type-specific therapies and drug targets for patients with neurodegenerative, psychiatric and CNS disordersNew on EvolcChemify
Automated chemistry systems that help pharmaceutical and materials partners design and synthesize moleculesNew on EvolcCizzle Biotechnology
Non-invasive blood test for early lung cancer detection based on the CIZ1B biomarker, aimed at healthcare providers and patientsNew on EvolcCNX Therapeutics
Licenses and distributes specialty medicines for CNS and critical care conditions in 60+ marketsNew on EvolcRemote-friendlyConcinnity Genetics
RNA-based control systems that make gene and cell therapies safer, designed for biopharma developersYoung companyNew on EvolcConstructivebio
Designs and manufactures new-to-nature proteins and peptides for pharmaceutical and industrial partnersNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cloudflare
- Cookiebot
- Google Analytics 4
- WordPress
- jQuery